Apparatus, system, and method for creating immunologically enhanced spaces in-vivo
First Claim
1. A method of creating antigen exposed dendritic cells within an immunologically protected/enhanced space in vivo in a mammal which comprises:
- a) removing the impact of soluble inhibitors of the mammal'"'"'s immune system in a defined space within the mammal'"'"'s body;
b) placing dendritic cells, dendritic cell precursors, or monocytes within the defined space; and
c) placing an antigen source within the defined space to allow a dendritic-antigen presentation process to proceed; and
wherein the defined space is created by providing one or more ligands that bind to soluble inhibitors of the mammal'"'"'s immune system.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention creates an immunologically protected/enhanced space in viva in a mammal by removing the impact of soluble inhibitors of the mammal'"'"'s immune system in a defined space within the body. Placing an antigen source within the defined protected space along with a monocyte-containing blood sample from the mammal being treated and a dendritic cell-inducing factor allows a dendritic-antigen presentation process to proceed to completion. The protected/enhanced space is created by surrounding the protected space with ligands which absorb and/or bind to one or more soluble inhibitors. The implant can be loaded with a patient'"'"'s cancer cells to treat cancer.
-
Citations
72 Claims
-
1. A method of creating antigen exposed dendritic cells within an immunologically protected/enhanced space in vivo in a mammal which comprises:
-
a) removing the impact of soluble inhibitors of the mammal'"'"'s immune system in a defined space within the mammal'"'"'s body; b) placing dendritic cells, dendritic cell precursors, or monocytes within the defined space; and c) placing an antigen source within the defined space to allow a dendritic-antigen presentation process to proceed; and wherein the defined space is created by providing one or more ligands that bind to soluble inhibitors of the mammal'"'"'s immune system. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. A method of treating a mammal with cancer wherein said method comprises:
-
a) providing an enclosed space within a mammal, said enclosed space comprising an internal region and a peripheral region wherein the peripheral region contains ligands that bind soluble inhibitors of the mammalian immune system and defines the internal region; b) placing within the internal region of the enclosed space; (i) one or more cancer cell antigens or a sample of the mammal'"'"'s cancer cells, (ii) a fraction of the mammal'"'"'s blood that contains monocyte cells, and (iii) one or more dendritic cell inducing factors; c) allowing dendritic cells to be induced from said monocyte cells whereby antigen presentation to said induced dendritic cells proceeds in the substantial absence of soluble inhibitors of the mammal'"'"'s immune system to form activated dendritic cells; and d) releasing the activated dendritic cells into the mammal'"'"'s vascular and/or immune system. - View Dependent Claims (14, 15, 16, 17)
-
-
18. A method of treating a mammal that has cancer with an implant device which comprises:
-
a) providing an implant device that contains a protective space for antigen presentation to dendritic cells wherein said protective space is surrounded by a soluble inhibitor adsorbent; b) placing one or more antigens or cells containing one or more antigens into the protective space of the implant device; c) placing a leukocyte fraction of blood obtained from the mammal and one or more dendritic cell inducing factors into the protective space of the implant device to induce formation of dendritic cells to form a loaded implant device; d) inserting the loaded implant device into the mammal; and e) releasing the induced dendritic cells from the implant into the mammal'"'"'s vascular and/or immune system, whereby the soluble inhibitor adsorbent allows antigen presentation to the induced dendritic cells to proceed. - View Dependent Claims (19, 20, 21, 22, 23, 24)
-
-
25. A method of treating a patient that has cancer with an implant device which comprises:
-
a) providing an implant device that contains a protective space for cancer antigen presentation to dendritic cells wherein said protective space is surrounded by a soluble inhibitor adsorbent; b) placing one or more cancer antigens or cancer cells into the protective space of the implant device; c) placing a leukocyte fraction of a blood sample obtained from the patient and one or more dendritic cell-inducing factors into the protective space of the implant device to induce formation of dendritic cells to form a loaded implant device; d) inserting the loaded implant device into the patient; and e) releasing the formed dendritic cells from the implant into the patient'"'"'s vascular and/or immune system; whereby the soluble inhibitor adsorbent allows antigen presentation to the induced dendritic cells to proceed. - View Dependent Claims (26, 27, 28, 29, 30, 31, 32)
-
-
33. A medical implant device for mammals which comprises:
-
a) a porous biocompatible outer case and b) an immunologically protected/enhanced inner space that contains (i) one or more antigens, (ii) one or more dendritic cell-inducing factors, (iii) a leukocyte fraction of a blood sample from a mammal who is the intended recipient of the medical implant device, and (iv) an adsorbent of soluble inhibitors to a mammalian immune system and c) a biodegradable plug. - View Dependent Claims (34, 35, 36, 37, 38, 39, 40, 41)
-
-
42. A medical implant device to produce an immune response to an antigen in a mammal which comprises:
-
a) a porous outer biocompatible case, b) a peripheral region within the biocompatible case that contains ligands which bind to soluble inhibitors to a mammalian immune system, c) an inner region which contains one or more antigens, a leukocyte fraction of a blood sample from the mammal to be treated and one or more dendritic cell inducing factors and d) a biodegradable plug, wherein the peripheral region and the inner region are separated by a membrane that is porous to cytokines and cytokine receptors but not to cells. - View Dependent Claims (43, 44, 45, 46, 47, 48, 49)
-
-
50. A medical implant device for mammals which comprises:
-
a) a biocompatible outer case that allows flow of blood into the implant device when implanted into a mammal and b) an immunologically protected inner space which contains (i) one or more antigens, (ii) dendritic cells and/or monocytes, (iii) a leukocyte attractant, and (iv) an adsorbent of soluble inhibitors to a mammalian immune system whereby a dendritic cell-antigen presentation process is able to proceed sufficiently to form activated dendritic cells. - View Dependent Claims (51, 52, 53, 54, 55, 56)
-
-
57. A medical implant device to treat cancer in a mammal which comprises:
-
a) a porous outer biocompatible case, b) a peripheral region within the biocompatible case that contains ligands which bind to soluble inhibitors to a mammalian immune system, c) an inner region which contains cancer antigens and a leukocyte fraction of a blood sample from the mammal to be treated for cancer, and d) a biodegradable plug wherein the peripheral region and the inner region are separated by a membrane that is porous to cytokines and cytokine receptors but impervious to cells. - View Dependent Claims (58, 59, 60, 61, 62, 63, 64)
-
-
65. A medical implant pellet to treat cancer in a mammal that can be administered with a needle and syringe which comprises:
-
a) a porous outer biocompatible case, b) a peripheral region within the biocompatible case that contains ligands which bind to soluble inhibitors to a mammalian immune system, c) an inner region which contains cancer antigens, a leukocyte fraction of a blood sample from the mammal to be treated for cancer and one or more dendritic cell inducing factors, and d) a biodegradable plug wherein the peripheral region and the inner region are separated by a membrane that is porous to cytokines and cytokine receptors but impervious to cells. - View Dependent Claims (66, 67, 68, 69, 70, 71, 72)
-
Specification